The first patient has been enrolled in the phase 3 PROSTATE-IQ trial being conducted in men with prostate cancer recurrence ...
U.S. deaths in 2024. 1.4 million new cases worldwide in 2022. Prostate cancer statistics can look scary: 34,250 U.S. deaths in 2024. 1.4 million new cases worldwide in 2022. Dr. Bruce Montgomery, a UW ...
U.S. deaths in 2024. 1.4 million new cases worldwide in 2022. Dr. Bruce Montgomery, a UW Medicine oncologist, hopes that ...
PSMA PET/CT trial will scan up to 1000 men in the UKA new kind of scan that could be key to improving the treatment of high-risk prostate cancer is ...
Additional Phase 2 data for vilastobart,a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC ...
Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN) Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET ...
PR+ breast cancer responds well to hormone therapy, underscoring the need for molecular insight and targeted treatment ...
ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...
The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...
The FDA has approved Stoboclo (denosumab-bmwo), a biosimilar to Prolia (denosumab), and Osenvelt (denosumab-bmwo), a biosimilar to Xgeva (denosumab).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback